Opthea to Host Investor Days in New York and Australia

Core Insights - Opthea Limited is preparing for an Investor Day on January 28, 2025, in New York City, followed by presentations in Sydney and Melbourne, to discuss the anticipated topline data from its pivotal trials for sozinibercept in wet AMD [1][2][3] Company Overview - Opthea is a clinical-stage biopharmaceutical company focused on developing novel therapies for retinal diseases, particularly wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) [8][9] - The lead product candidate, sozinibercept, is currently being evaluated in two pivotal Phase 3 clinical trials (COAST and ShORe) aimed at improving efficacy and vision outcomes when used in combination with standard anti-VEGF-A therapies [9] Management and Expertise - The Investor Day will feature presentations from Charles C. Wykoff, MD, PhD, a leading retina specialist and Chief Investigator for the COAST trial, and Mike Campbell, Chief Commercial Officer, who has extensive experience in launching treatments for retinal diseases [4][5][6] Event Details - The New York event will include a live webcast and a question-and-answer session, concluding around 3:00 PM ET, with a replay available on the company's website [2] - In-person presentations will also take place in Sydney on February 3 and Melbourne on February 5, 2025 [3]